Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
University of Michigan Rogel Cancer Center
NRG Oncology
Thomas Jefferson University
Mayo Clinic
University of Iowa
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Emory University
Baptist Health South Florida
Mayo Clinic
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
NRG Oncology
NRG Oncology
Mayo Clinic
Children's Oncology Group
Northwestern University
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center